Synergistic effects of liposomes encapsulating atorvastatin calcium and curcumin and targeting dysfunctional endothelial cells in reducing atherosclerosis
Open Access
- 1 January 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in International Journal of Nanomedicine
- Vol. ume 14, 649-665
- https://doi.org/10.2147/ijn.s189819
Abstract
Background: Atherosclerosis is a major cardiovascular disease that causes ischemia of the heart, brain, or extremities, and can lead to infarction. The hypolipidemic agent atorvastatin calcium (Ato) alleviates atherosclerosis by reducing plasma lipid and inflammatory factors. However, the low bioavailability of Ato limits its widespread use and clinical effectiveness. Curcumin (Cur), a natural polyphenol with antioxidation and anti-inflammation bioactivities, has potential anti-atherosclerosis activity and may reduce Ato-induced cytotoxicity. Materials and methods: Liposomes modified using a targeting ligand (E-selectin-binding peptide) were prepared to co-deliver Ato and Cur to dysfunctional endothelial cells (ECs) overexpressing E-selectin. Molecules involved in the inhibition of adhesion (E-selectin and intercellular cell adhesion molecule-1 [ICAM-1]) and inflammation (IL-6 and monocyte chemotactic protein 1 [MCP-1]) in human aortic endothelial cells were evaluated using real-time quantitative PCR, flow cytometry, and immunofluorescence staining. The antiatherosclerosis effects of liposomes co-loaded with Ato and Cur in vivo were evaluated using ApoE knockout (ApoE-/-) mice. Results: Targeted liposomes delivered Ato and Cur to dysfunctional ECs, resulting in synergistic suppression of adhesion molecules (E-selectin and ICAM-1) and plasma lipid levels. Moreover, this treatment reduced foam cell formation and the secretion of inflammatory factors (IL-6 and MCP-1) by blocking monocyte migration into the intima. In addition, Cur successfully reduced Ato-inducible cytotoxicity. Conclusion: Both in vitro and in vivo experiments demonstrated that cell-targeted co-delivery of Ato and Cur to dysfunctional ECs drastically reduces atherosclerotic lesions with fewer side effects than either Ato or Cur alone.Keywords
This publication has 55 references indexed in Scilit:
- Electrostatically Mediated Liposome Fusion and Lipid Exchange with a Nanoparticle-Supported Bilayer for Control of Surface Charge, Drug Containment, and DeliveryJournal of the American Chemical Society, 2009
- Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseasesThe International Journal of Biochemistry & Cell Biology, 2009
- Effects of Atorvastatin on Vascular Intimal Hyperplasia: An Experimental Rodent ModelAngiology, 2008
- Inflammation in AtherosclerosisJournal of the American College of Cardiology, 2006
- Macrophages, inflammation, and atherosclerosisInternational Journal of Obesity, 2003
- Atherosclerotic Lesions Grow Through Recruitment and Proliferation of Circulating Monocytes in a Murine ModelThe American Journal of Pathology, 2002
- Monocyte Chemoattractant Protein-1 Induces Proliferation and Interleukin-6 Production in Human Smooth Muscle Cells by Differential Activation of Nuclear Factor-κB and Activator Protein-1Arteriosclerosis, Thrombosis, and Vascular Biology, 2002
- HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosisLeukemia, 2002
- Inflammation and AtherosclerosisJournal of the American College of Cardiology, 2002
- Immune and inflammatory mechanisms in the development of atherosclerosisHeart, 1993